Thesis
CAPTAIN data shows TULSA-PRO halves surgical harm vs. robotic prostatectomy; survival to cash-flow breakeven determines whether the commercial story completes
TULSA-PRO, a transurethral ultrasound ablation system for localized prostate cancer, just posted Level 1 randomized data showing 50% versus 24% preservation of both continence and erectile function against robotic prostatectomy. Revenue growing at 56% guidance with 78% gross margins and expanding payer coverage is the commercial engine, but $38M cash at roughly $10M quarterly burn reaches only Q2 2027. The thesis resolves on whether revenue accelerates fast enough to avoid a dilutive raise before breakeven, with payer adoption breadth the single variable most likely to determine that outcome.
Focus
TULSA-PRO commercial revenue ramp toward $25M FY2026 guidance on payer coverage gains
Q4 2026
Bull
Record Q2 purchase orders of $7M with $3.1M already shipped into Q3 provide strong revenue visibility; if the $70M qualified sales pipeline converts even partially and additional large commercial payers follow Humana's coverage decision, management's $25M guidance could prove conservative. Gross margin expansion to 78% in Q2 demonstrates operating leverage that could meaningfully narrow the quarterly cash burn as volumes scale.
Bear
Cash of $38.3M against approximately $10M quarterly operating burn leaves roughly three to four quarters of runway, meaning any revenue shortfall or elongated hospital capital budget cycles could force dilutive financing before the business reaches cash-flow breakeven. Payer coverage additions add covered lives but do not guarantee procedure utilization growth if urologists remain slow to adopt or if hospital capital committees defer TULSA-PRO system purchases.
Unlock the full thesis for PROF.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.